Loading
companiesCompany
OSE Immunotherapeutics
OSE Immunotherapeutics develops immune treatments for cancer and inflammatory disease. Its lead cancer product is an off-the-shelf vaccine for lung cancer patients whose immunotherapy has stopped working, now in a late-stage trial.
Overview
OSE Immunotherapeutics SA (Euronext Paris: OSE), based in Nantes, is a clinical-stage company with platforms in immuno-oncology and immuno-inflammation. Tedopi (OSE2101) is an off-the-shelf neo-epitope T cell vaccine for HLA-A2 positive patients, in the phase 3 ARTEMIA trial in non-small cell lung cancer after checkpoint inhibitor failure; the trial received a second positive Independent Data Monitoring Committee recommendation in February 2026, and Tedopi showed positive phase 2 results in recurrent ovarian cancer (TEDOVA, ASCO 2026). OSE-279 is an anti-PD-1 antibody, with partnered programmes ABBV-230 (AbbVie) and BI 770371 (Boehringer Ingelheim). Outside oncology, lusvertikimab (anti-IL-7R) targets inflammatory bowel disease and pegrizeprument is partnered with Veloxis in transplantation. In May 2026 OSE signed a flexible bridge equity financing with IRIS Capital for up to about EUR 19.3 million, extending cash runway to December 2026.
Headquarters
Nantes, FR
Scorecard
All companies#282of 1244 companies, score 16
- phase 3 +3
- targets +6
- modalities +2
- registry trials +5
0 approved, 1 in phase 3, 0 earlier, 3 targets, 6 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Crossover · Flexible bridge equity financing (warrants) with IRIS Capital Investment: up to 4 million new shares, gross proceeds up to about EUR 19.3 million over 24 months at the then share price | 2026 | undisclosed | ose-immuno.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · OSE.PA
Stage
Public
Website
Phase 3vaccine
OSE2101 is an experimental cancer vaccine from OSE Immunotherapeutics in phase 3 trials for non-small-cell lung cancer, aimed at HER2 and CEACAM5.
Notes
top- Founding year not sourced.
Similar pages
- CompanyMendus
- TrialCombining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer
Shares Off-the-shelf cancer vaccines, Immune checkpoint inhibitors.
- CompanyAdventris Pharmaceuticals
Shares Off-the-shelf cancer vaccines, Non-small-cell lung cancer.
- InstitutionThe Wistar Institute
Shares Off-the-shelf cancer vaccines, Monoclonal antibodies, Ovarian cancer.
- PersonJames L. Gulley
Shares Off-the-shelf cancer vaccines, Immune checkpoint inhibitors.
- TrialPhase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can
Shares Off-the-shelf cancer vaccines, Immune checkpoint inhibitors.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares Off-the-shelf cancer vaccines, Monoclonal antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PersonElizabeth M. Jaffee
Shares Off-the-shelf cancer vaccines, Immune checkpoint inhibitors.
cancers
fronts
technologies
targets
drugs
Phase 3vaccine